Citadel Advisors
CNTA

Citadel Advisors’s Centessa Pharmaceuticals CNTA Stock Holding History

Citadel Advisors’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.32M Buy
83,600
+61,100
+272% +$1.56M ﹤0.01% 5066
2025
Q4 		$563K Sell
22,500
-9,100
-29% -$230K ﹤0.01% 8742
2025
Q3 		$766K Sell
31,600
-3,900
-11% -$69.3K ﹤0.01% 8131
2025
Q2 		$466K Buy
35,500
+18,400
+108% +$233K ﹤0.01% 8795
2025
Q1 		$246K Buy
17,100
+10,100
+144% +$165K ﹤0.01% 10024
2024
Q4 		$117K Buy
7,000
+1,100
+19% +$18.2K ﹤0.01% 11224
2024
Q3 		$94.3K Sell
5,900
-6,200
-51% -$76K ﹤0.01% 11196
2024
Q2 		$109K Sell
12,100
-5,600
-32% -$53.1K ﹤0.01% 10795
2024
Q1 		$200K Buy
17,700
+8,100
+84% +$76.7K ﹤0.01% 10318
2023
Q4 		$76.4K Buy
9,600
+2,600
+37% +$17.4K ﹤0.01% 11282
2023
Q3 		$45.3K Buy
7,000
+5,800
+483% +$39.7K ﹤0.01% 11861
2023
Q2 		$7.43K Buy
+1,200
New +$5.69K ﹤0.01% 13375

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Citadel Advisors's CNTA Position: Q1 2026 in Review

Citadel Advisors increased its Centessa Pharmaceuticals (CNTA) stake by 15% in Q1 2026, buying an estimated $2M and bringing the position to 598,197 shares worth $23.8M. The position accounts for ﹤0.01% of the portfolio, ranked #2123.

Citadel Advisors first reported a position in CNTA in Q2 2021 and has held it in 18 quarters since. 161 funds tracked by Wall St. Rank hold CNTA as of Q1 2026.

  • Citadel Advisors held 598,197 shares of Centessa Pharmaceuticals worth $23.8M as of Q1 2026.
  • Citadel Advisors bought 78,235 Centessa Pharmaceuticals shares in Q1 2026, an estimated $2M.
  • Centessa Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2123 holding.
  • Citadel Advisors first reported a position in Centessa Pharmaceuticals in Q2 2021 and has held it in 18 quarters since.
  • 161 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.